— Publications

2018 Full-Year Results 

All financial reports

— Media releases

January 31, 2019

Valneva Reports Positive Initial Booster Data and Final Phase 1 Data for its Lyme Disease Vaccine Candidate

Read more

— Financial calendar

Upcoming events

Q1 2019 Interim Results
May 2, 2019

All dates

— Lyme Disease

Download brochure


— Our responsibility

Committed to people, protecting lives and the environment

Learn more

play video
“We have the only
clinical-stage vaccine program
against Lyme disease 

Valneva's CEO Thomas Lingelbach
comments on Group Strategy

Subscribe to our Newsletter


Contact Investor Relations


Please update your browser...